Nectar Life Sciences Limited

BSE: 532649 NSE: NECLIFE
Nectar Life Sciences Limited - pharma in Derabassi, Punjab, India. FY 2026 financials & compliance.
CIN L24232PB1995PLC016664 Incorporated 27 June 1995 ROC Chandigarh HQ Derabassi, Punjab, India
Active Listed - NSE: NECLIFE · BSE: 532649 Public Limited Company pharma
Data last updated
Market Cap
₹199 Cr
NECLIFE · NSE
Share Price
₹10.23
-2.57% today
EBITDA
−₹296 Cr
FY 2025-26
Net Profit
−₹241 Cr
FY 2025-26 · -111.6% YoY
ROE
-31.3%
ROCE 0.1%
Debt / Equity
0.38
Interest cover -12.2x
Authorised capital
₹35 Cr
Registered with MCA
Paid-up capital
₹22.43 Cr
Issued & subscribed

About Nectar Life Sciences Limited

Data last updated:

Nectar Life Sciences Limited is a public limited company based in Derabassi, Punjab, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 June 1995 and has been in existence for over 31 years.

The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L24232PB1995PLC016664. Its GSTIN is 03AABCS6468G1ZD (Punjab). The company holds 18 GST registrations, of which 5 are active. Its shares are listed on BSE: 532649 and NSE: NECLIFE.

The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹22.43 Cr. It was formerly known as Surya Medicare Limited. It is led by directors including Sanjiv Goyal (Managing Director) and Sushil Kapoor (Whole-Time Director).

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507.

The net worth stands at ₹582.3 Cr (down 39.1% YoY). Total assets are valued at ₹595.56 Cr (down 61.52% YoY).

The company has about 1,814 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Nectar Lifesciences. As per MCA filings, the company has open charges of ₹60.47 Lakh and satisfied charges of ₹6,249.44 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website neclife.com.

Company Details of Nectar Life Sciences Limited
CIN L24232PB1995PLC016664
Registration Number 016664
Incorporation Date 27 June 1995
ROC Chandigarh
Listing Status Listed (BSE: 532649, NSE: NECLIFE)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sanjiv Goyal Managing Director Sushil Kapoor Whole-Time Director Indu Pal Kaur Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    neclife.com
  • Social Media
    Locked
  • Registered Address
    Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers
Comprehensive company report
Nectar Life Sciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Nectar Life Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Nectar Life Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Nectar Life Sciences

Nectar Life Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232PB1995PLC016664, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24232PB1995PLC016664Current
U24232PB1995PLC016664Previous
L21000PB1995PLC016664Previous

Associated Brands with Nectar Life Sciences

Nectar Life Sciences operates one associated brand: Nectar Lifesciences. Each brand links to its own profile.

BrandDescriptionWebsite
Nectar Lifesciences
Cephalosporin APIs and generic formulations are manufactured.neclife.com

Business Activity of Nectar Life Sciences

The main business activity of Nectar Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details for Nectar Life Sciences Limited

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Nectar Life Sciences

Nectar Life Sciences Limited is audited by DEEPAK JINDAL & CO. for the financial year 2025.

NameStatusAppointment DateCessation Date
DEEPAK JINDAL & CO.LockedLockedLocked
Premium access

Complete auditor history for Nectar Life Sciences Limited

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Nectar Life Sciences Limited

Nectar Life Sciences has 6 current directors and 26 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Indu Pal Kaur
Also directs: Casanova R&D Private Limited
Director02 Aug 20224 Years 2 MonthsCurrent
Rupinder Tewari
Also directs: Nureca Limited
Director11 Feb 20197 Years 7 MonthsCurrent
Kuldip Kumar Bhasin
Also directs: Nureca Limited
Director21 Sep 20215 Years 0 MonthsCurrent
Sushil KapoorWhole-Time Director04 Dec 20250 Years 10 MonthsCurrent
Sanjiv Goyal
Also directs: Nectar Organics Private Limited
Managing Director27 Jun 199531 Years 3 MonthsCurrent
Surulichamy SenthilkumarDirector10 Nov 20250 Years 10 MonthsCurrent
View all directors

Financials of Nectar Life Sciences Limited FY 2025-26 filings available

Nectar Life Sciences Limited reported revenue of ₹- (down 100% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹0.00 Cr
-100.0% YoY
EBITDA
−₹296 Cr
-902.2% YoY
Profit After Tax
−₹241 Cr
-111.6% YoY
Net Worth
₹582 Cr
-39.1% YoY
Total Assets
₹596 Cr
-61.5% YoY
Total Debt
₹0.00 Cr
-100.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.001,6701,6841,5241,6691,5432,366
Revenue growth-82.6%+10.9%+4.2%-2.6%+3.5%-32.0%-14.8%
EBITDA(296)(29.56)15253.0115983.72220
EBITDA margin--1.8%+9.0%+3.5%+9.5%+5.4%+9.3%
Profit before tax(323)(162)18.27(42.42)34.07(84.78)37.46
Net profit(241)(114)4.88(64.69)18.12(47.87)31.56
Net profit margin--6.8%+0.3%-4.3%+1.1%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.08)1.12(3.27)1.42
Balance sheet
Total assets5961,5481,7131,8261,9561,9761,926
Net worth5829561,0691,0651,0881,0621,136
Total debt0.00582636754860903779
Cash & bank11219.2219.8117.5817.8125.5421.29
Net working capital2147378068679198261,024
Cash flow
Cash from operations(349)16922513495.0121.38285
Cash from investing1,208(41.93)(17.03)51.7016.64(28.62)(33.13)
Cash from financing(767)(128)(205)(186)(119)11.49(252)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.000.715.240.010.015.74
Revenue growth (YoY)-99.8%+9997.0%+9997.0%+9997.0%-98.5%+9997.0%+9997.0%-98.6%
Other income3.246.2935.460.030.320.188.086.52
EBITDA(27.27)(87.95)(1.92)(176)(63.39)(130)(0.04)(0.58)
EBITDA margin-----1212.0%---10.1%
Depreciation0.110.080.060.110.530.300.070.45
Interest0.165.9030.220.000.000.000.000.00
Profit before tax(24.30)(87.64)3.26(176)(63.60)(130)7.975.49
Tax(8.90)(19.72)(11.02)0.16(0.37)(0.06)0.12(0.12)
Net profit(15.40)(67.92)14.28(176)(63.23)(130)7.855.61
EPS (₹)(0.79)(3.38)0.64(7.85)(2.82)(5.80)0.350.25
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.000.001,6841,5241,6681,5422,363
Revenue growth+158.6%-92.5%+4.3%-2.7%+3.5%-32.0%-14.9%
EBITDA(296)(115)15254.7315983.82218
EBITDA margin--+9.0%+3.6%+9.5%+5.4%+9.2%
Profit before tax(323)(113)18.28(40.69)34.35(84.67)35.75
Net profit(241)(114)4.83(62.96)15.91(47.76)29.85
Net profit margin--+0.3%-4.1%+1.0%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.00)1.13(3.26)1.34
Balance sheet
Total assets5861,5481,7131,8261,9551,9751,925
Net worth5829561,0691,0651,0871,0611,135
Total debt0.00582636754860903779
Cash & bank10819.2219.8017.5717.7425.4321.23
Net working capital2117378068679188251,023
Cash flow
Cash from operations(417)16922513395.0421.33286
Cash from investing1,205(41.93)(17.03)52.0316.64(28.62)(33.14)
Cash from financing(699)(128)(205)(186)(119)11.49(252)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.005.715.240.014555.74
Revenue growth (YoY)-99.8%+9997.0%+9997.0%-12.7%-98.5%+9997.0%+0.5%-98.6%
Other income6.176.2935.460.030.320.180.576.52
Total expenses27.6889.231.9218268.631304106.32
EBITDA(27.24)(87.94)(1.92)(176)(63.39)(130)44.71(0.58)
EBITDA margin----3520.2%-1212.0%-+9.8%-10.1%
Depreciation0.110.080.060.200.530.3015.610.45
Interest0.165.9030.220.000.000.0017.120.00
Profit before tax(21.34)(87.63)3.26(176)(63.60)(130)12.555.49
Tax(8.20)(19.71)(11.02)(0.18)(0.37)(0.06)4.71(0.12)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.000.715.240.010.015.74
Revenue growth (YoY)-99.8%+9997.0%+9997.0%+9997.0%-98.5%+9997.0%+9997.0%-98.6%
Other income3.246.2935.460.030.320.188.086.52
EBITDA(27.27)(87.95)(1.92)(176)(63.39)(130)(0.04)(0.58)
EBITDA margin-----1212.0%---10.1%
Depreciation0.110.080.060.110.530.300.070.45
Interest0.165.9030.220.000.000.000.000.00
Profit before tax(24.30)(87.64)3.26(176)(63.60)(130)7.975.49
Tax(8.90)(19.72)(11.02)0.16(0.37)(0.06)0.12(0.12)
Net profit(15.40)(67.92)14.28(176)(63.23)(130)7.855.61
EPS (₹)(0.79)(3.38)0.64(7.85)(2.82)(5.80)0.350.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.001,6701,6841,5241,6691,5432,366
Revenue growth-82.6%+10.9%+4.2%-2.6%+3.5%-32.0%-14.8%
Other income9.294.9914.5843.1811.323.794.36
Total expenses2961,7001,5331,4711,5101,4602,147
Employee cost0.9093.6181.7175.1371.9170.5978.19
EBITDA(296)(29.56)15253.0115983.72220
EBITDA margin--1.8%+9.0%+3.5%+9.5%+5.4%+9.3%
Depreciation0.3462.3960.7259.1256.9760.2560.77
Interest36.1374.5887.1479.4978.81112126
Profit before tax(323)(162)18.27(42.42)34.07(84.78)37.46
Tax(30.53)(47.85)13.28(18.24)9.03(11.50)5.68
Net profit(241)(114)4.88(64.69)18.12(47.87)31.56
Net profit margin--6.8%+0.3%-4.3%+1.1%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.08)1.12(3.27)1.42
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.4322.4322.4322.4322.4322.4322.43
Reserves & surplus5639341,0471,0421,0651,0401,114
Shareholders' funds (net worth)5829561,0691,0651,0881,0621,136
Minority interest0.000.000.000.000.000.000.00
Secured loans0.00487540672784840760
Unsecured loans0.0094.6896.0181.4576.0863.1718.45
Total debt0.00582636754860903779
Total liabilities5961,5481,7131,8261,9561,9761,926
Assets
Gross block1071,6521,5991,5581,5631,5561,509
Net block105633643662723772785
Capital work in progress0.0056.7365.7577.7885.1098.63115
Investments13.210.770.730.550.700.690.40
Inventories0.30690709673660588978
Sundry debtors0.00345379280447375396
Cash & bank balances11219.2219.8117.5817.8125.5421.29
Loans & advances128182175261230250220
Total current assets2401,2371,2831,2311,3541,2381,615
Total current liabilities26.06500478364435412591
Net working capital2147378068679198261,024
Total assets5961,5481,7131,8261,9561,9761,926
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.2219.8117.5817.8125.5421.2921.33
Net cash from operating activities(349)16922513495.0121.38285
Net cash from investing activities1,208(41.93)(17.03)51.7016.64(28.62)(33.13)
Net cash from financing activities(767)(128)(205)(186)(119)11.49(252)
Net change in cash92.91(0.58)2.23(0.23)(7.73)4.25(0.03)
Closing cash11219.2219.8117.5817.8125.5421.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9997.0%-0.8%+10.5%-8.7%+8.1%-34.8%-15.0%
EBITDA growth-902.2%-+185.9%-66.6%+89.4%-61.9%-16.8%
PBT growth-100.2%-+9998.0%-+9998.0%--36.3%
Net income growth-111.6%-+9998.0%-+9998.0%--33.9%
Revenue CAGR (3Y)-100.0%+0.0%+3.0%-13.7%-15.7%-6.3%+12.9%
EBITDA CAGR (3Y)--+21.9%-37.7%-15.7%-29.2%-0.7%
Profitability & leverage
Net income margin--6.8%+0.3%-1.6%+1.5%-4.8%+1.3%
Return on capital employed+0.1%-5.3%+6.0%-0.2%+5.3%+2.7%+8.3%
Return on net worth-31.3%-11.2%+0.5%-6.0%+1.7%-4.4%+2.8%
Debt / equity0.380.600.650.750.820.770.75
Long-term debt / equity0.050.100.170.240.200.110.13
Interest cover-12.18-81.1195.94-1,300.9877.60477.3879.17
Efficiency & per share
Fixed asset turnover0.001.171.221.121.231.151.76
Inventory turnover0.002.732.792.623.092.252.79
Debtors turnover0.005.275.854.814.694.585.54
EPS (₹)(15.08)(5.07)0.22(1.08)1.12(3.27)1.42
Dividend per share (₹)0.000.000.000.000.000.000.05
Book value per share (₹)29.9842.6347.6847.4748.5147.3650.66
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.005.715.240.014555.74
Revenue growth (YoY)-99.8%+9997.0%+9997.0%-12.7%-98.5%+9997.0%+0.5%-98.6%
Other income6.176.2935.460.030.320.180.576.52
Total expenses27.6889.231.9218268.631304106.32
EBITDA(27.24)(87.94)(1.92)(176)(63.39)(130)44.71(0.58)
EBITDA margin----3520.2%-1212.0%-+9.8%-10.1%
Depreciation0.110.080.060.200.530.3015.610.45
Interest0.165.9030.220.000.000.0017.120.00
Profit before tax(21.34)(87.63)3.26(176)(63.60)(130)12.555.49
Tax(8.20)(19.71)(11.02)(0.18)(0.37)(0.06)4.71(0.12)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.000.001,6841,5241,6681,5422,363
Revenue growth+158.6%-92.5%+4.3%-2.7%+3.5%-32.0%-14.9%
Other income9.291.8814.5843.1811.323.794.32
Total expenses2961151,5331,4691,5091,4582,145
Employee cost0.890.0981.7175.1471.9170.5578.19
EBITDA(296)(115)15254.7315983.82218
EBITDA margin--+9.0%+3.6%+9.5%+5.4%+9.2%
Depreciation0.340.6260.7259.1256.9760.2560.77
Interest36.130.0087.1479.4878.81112126
Profit before tax(323)(113)18.28(40.69)34.35(84.67)35.75
Tax(30.53)0.3813.27(18.24)9.03(11.50)5.68
Net profit(241)(114)4.83(62.96)15.91(47.76)29.85
Net profit margin--+0.3%-4.1%+1.0%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.00)1.13(3.26)1.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.4322.4322.4322.4322.4322.4322.43
Reserves & surplus5639341,0471,0421,0641,0381,112
Shareholders' funds (net worth)5829561,0691,0651,0871,0611,135
Secured loans0.00487540672784825760
Unsecured loans0.0094.6896.0181.4476.0877.9918.45
Total debt0.00582636754860903779
Total liabilities5861,5481,7131,8261,9551,9751,925
Assets
Gross block5.911,6521,5991,5581,5631,5561,509
Net block3.45633643662723772785
Capital work in progress0.0056.7365.7577.7885.1098.63115
Investments13.460.770.740.561.031.030.74
Inventories0.30690709673660587975
Sundry debtors0.00345379280447375397
Cash & bank balances10819.2219.8017.5717.7425.4321.23
Loans & advances128182175261229250220
Total current assets2371,2371,2831,2311,3531,2371,614
Total current liabilities25.97500478364435412591
Net working capital2117378068679188251,023
Total assets5861,5481,7131,8261,9551,9751,925
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.2219.8017.5717.7425.4321.2320.58
Net cash from operating activities(417)16922513395.0421.33286
Net cash from investing activities1,205(41.93)(17.03)52.0316.64(28.62)(33.14)
Net cash from financing activities(699)(128)(205)(186)(119)11.49(252)
Net change in cash88.91(0.58)2.23(0.17)(7.70)4.200.65
Closing cash10819.2219.8017.5717.7425.4321.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9997.0%+9997.0%+10.5%-8.7%+8.2%-34.8%-15.2%
EBITDA growth-158.6%-+176.9%-65.5%+89.5%-61.6%-17.4%
PBT growth-185.4%-+9998.0%-+9998.0%--39.0%
Net income growth-111.6%-+9998.0%-+9998.0%--37.2%
Revenue CAGR (3Y)-100.0%-100.0%+3.0%-13.6%-15.7%-6.3%+12.9%
EBITDA CAGR (3Y)--+21.8%-36.9%-15.6%-29.2%-0.9%
Profitability & leverage
Net income margin--+0.3%-1.5%+1.5%-4.8%+1.3%
Return on capital employed+0.1%+0.1%+6.0%-0.1%+5.3%+2.7%+8.2%
Return on net worth-31.3%-11.2%+0.5%-5.9%+1.5%-4.4%+2.7%
Debt / equity0.380.600.650.750.820.770.75
Long-term debt / equity0.040.100.170.240.200.110.13
Interest cover-12.180.0095.93-1,810.4877.39475.3180.01
Efficiency & per share
Fixed asset turnover0.000.001.221.121.231.151.76
Inventory turnover0.000.002.792.623.092.262.79
Debtors turnover0.000.005.854.814.694.575.51
EPS (₹)(15.08)(5.07)0.22(1.00)1.13(3.26)1.34
Dividend per share (₹)0.000.000.000.000.000.000.05
Book value per share (₹)29.9842.6347.6847.4748.4647.3050.59
Want more history and ratios?
You're viewing the latest exchange-filed financials for Nectar Life Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Nectar Life Sciences Limited

Shareholding for the quarter ended Sep 2026: promoters hold 51.80%, foreign institutional investors hold 0.50%, domestic institutional investors hold 3.80% and retail and other public shareholders hold 43.90%.

Promoters: 51.80%DII (Domestic Institutional): 3.80%FII (Foreign Institutional): 0.50%Retail & Others: 43.90%
Sep 2026
QUARTER
51.80% Promoters
3.80% DII (Domestic Institutional)
0.50% FII (Foreign Institutional)
43.90% Retail & Others
Promoter holding - history
Now 51.80% · Sep 2026High 51.80% · Jun 2026Low 44.90% · Dec 2025
43%45.5%48%50.5%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 44.90%Mar 2026: 44.90%Jun 2026: 51.80%Sep 2026: 51.80%51.80%44.90%51.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters51.80%51.80%44.90%44.90%
Public48.20%48.20%55.10%55.10%

Charges & Borrowings of Nectar Life Sciences

Open charges
₹60.47 Lakh
Satisfied charges
₹6,249.44 Cr
Breakdown by lending institutions
Others₹1,377.64 Cr
Sbicap Trustee Company Limited₹1,338.35 Cr
Punjab National Bank₹790.10 Cr
State Bank of India₹771.01 Cr
Export-Import Bank of India₹430.00 Cr
Others₹1,542.33 Cr
Latest charge details
DateLenderAmountStatus
27 Dec 2023Hdfc Bank Limited₹60.47 LakhSatisfied
28 Jun 2022Hdfc Bank Limited₹20 LakhSatisfied
01 Dec 2021Hdfc Bank Limited₹20 LakhSatisfied
14 Jul 2021Hdfc Bank Limited₹6 LakhSatisfied
21 Jun 2021Sbicap Trustee Company Limited₹1,338.35 CrSatisfied

Total charge records: 111 View all charges

Employees and EPFO Compliance at Nectar Life Sciences

Nectar Life Sciences Limited has a workforce of 1,814 employees as of Nov 28, 2025.

Employee count
1,814
Active EPFO establishments
4
Employee growth
0.39%
Premium access

Employee and EPFO history for Nectar Life Sciences Limited

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Nectar Life Sciences

Nectar Life Sciences has 18 GST registrations: 5 active and 13 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
18
Active
5
Cancelled / inactive
13
GSTINStateStatusRegistered on
03AABCS6468G1ZDPunjabActive01 Jul 2017
02AABCS6468G1ZFHimachal PradeshActive01 Jul 2017
01AABCS6468G2ZGJammu and KashmirActive08 Jul 2017
04AABCS6468G3Z9ChandigarhActive16 Jul 2017
Premium access

GST registrations and filing compliance for Nectar Life Sciences Limited

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Nectar Life Sciences

Premium access

Credit ratings, litigation, and regulatory alerts for Nectar Life Sciences Limited

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Nectar Life Sciences

Premium access

MSME payment history for Nectar Life Sciences Limited

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Nectar Life Sciences

Premium access

Corporate group structure for Nectar Life Sciences Limited

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Nectar Life Sciences

Premium access

MCA filings and documents for Nectar Life Sciences Limited

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Nectar Life Sciences

Directors
04 Dec 2025
Sushil Kapoor was appointed as a Whole-time director on 04 Dec 2025 & has been associated with this company since 10 months.
Charges
14 Nov 2025
A charge registered on 27 Dec 2023 via Charge ID 100841946 with Hdfc Bank Limited was fully satisfied on 14 Nov 2025.
Directors
10 Nov 2025
Surulichamy Senthilkumar was appointed as a Director on 10 Nov 2025 & has been associated with this company since 10 months 24 days.
Charges
21 Oct 2025
A charge registered on 21 Jun 2021 via Charge ID 100458233 with Sbicap Trustee Company Limited was fully satisfied on 21 Oct 2025.
Activity
29 Sep 2025
Nectar Life Sciences Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
01 Aug 2025
A charge registered on 28 Jun 2022 via Charge ID 100593892 with Hdfc Bank Limited was fully satisfied on 01 Aug 2025.

Recent News on Nectar Life Sciences

Frequently Asked Questions about Nectar Life Sciences Limited

Nectar Life Sciences is an active public limited company based in Derabassi, Punjab, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 June 1995 (31+ years old) and is registered under CIN L24232PB1995PLC016664. Listed on BSE: 532649 and NSE: NECLIFE.

Nectar Life Sciences has 6 current directors:

The GSTIN of Nectar Life Sciences is 03AABCS6468G1ZD, registered in Punjab. The company has 18 GST registrations in all, of which 5 are active and 13 are cancelled or inactive. Other active GSTINs include 02AABCS6468G1ZF (Himachal Pradesh), 01AABCS6468G2ZG (Jammu and Kashmir), 04AABCS6468G3Z9 (Chandigarh).

The CIN (Corporate Identification Number) of Nectar Life Sciences is L24232PB1995PLC016664. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Nectar Life Sciences is listed on both BSE (code: 532649) and NSE (symbol: NECLIFE).

Nectar Life Sciences was incorporated on 27 June 1995, making it 31+ years old. It is registered with the Registrar of Companies, Chandigarh.

Nectar Life Sciences can be reached through the website neclife.com. Its registered office is in Derabassi, Punjab, India.

The registered office of Nectar Life Sciences is at Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507.

Nectar Life Sciences has an authorised share capital of ₹35 Cr and a paid-up capital of ₹22.43 Cr.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available